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dian survival of the subset of patients with stage IIIB locoregional (LR) 
disease. The results for this subgroup are now available and are reported 
here together with the updated survival for the overall population. 
Method: 171 patients with ECOG 0-2 stage IIIB/IV NSCLC that had 
stable or responding disease after any ﬁrst-line chemotherapy (CT) 
with or without radiotherapy were randomized 1:1 to receive either L-
BLP25 plus best supportive care (BSC) or BSC alone. Randomization 
was stratiﬁed by stage of disease (IIIB LR or stage IIIB with malignant 
pleural effusion and stage IV). Patients in the L-BLP25 arm received a 
single i.v. dose of cyclophosphamide 300mg/m2 followed by 8 weekly 
sc immunizations with L-BLP25 (1000μg). Subsequent immunizations 
were administered at 6-wk intervals. An analysis of 65 patients with 
stage IIIB LR disease was conducted, and the results are shown in the 
table below together with the updated 3 year survival for the overall 
population. 
Results: 
 Overall Population Stage IIIB subgroup
 BSC L-BLP25 + BSC Total BSC
L-BLP25 + 
BSC Total
N 83 88 171 30 35 64
Median 
follow up 
(mths)
56 51 52 57 53 53
Median 
Survival 
(mths)
13.0 17.2 p=0.085* 13.3 30.6 p=NS**
95% CI 11.2, 16.2 12.9, 24.2  9.6, 28.1 13.4, -  
Hazard 
Ratio   0.75   0.55
95% CI   0.53, 1.04   0.30, 1.00
1 yr OS 46 (55) 55 (63)  17 (57) 24 (69)  
2 yr OS 22 (27) 36 (41)  10 (33) 20 (57)  
3 yr OS 14 (17) 27 (31)  8 (27) 17 (49)  
* P-value; adjusted for multiple comparisons. Unadjusted p-values for this subgroup based on a Cox 
model including response to ﬁrst-line treatment; 0.0497
**P-value of the primary analysis (March 2004) was p=0.112 
Conclusion: A 17.3 month difference in median survival and 45% 
reduction in mortality were seen with maintenance therapy with 
L-BLP25 in patients with stage IIIB LR NSCLC. The difference in 
efﬁcacy identiﬁed in this subgroup versus patients with IIIB MPE or 
stage IV disease, could potentially be a result of lower tumor burden 
or less advanced disease. On the basis of these results, a phase III trial 
(“START”) has been initiated to investigate the addition of mainte-
nance therapy with L-BLP25 to BSC in patients with unresectable stage 
III NSCLC. 
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Background: The clusterin gene is frequently expressed in NSCLC 
and encodes a cytoprotective chaperone protein that is upregulated in 
response to apoptotic stimuli such as chemotherapy. OGX-011 is a sec-
ond-generation antisense oligonucleotide that inhibits clusterin expres-
sion, thus enhancing the apoptotic effects of chemotherapy. Previous 
phase I studies with docetaxel suggested an OGX-011 dose of 640mg 
was feasible and biologically active; therefore, the current study began 
with a run-in phase with 480mg of OGX-011.
Methods: Eligibility criteria: stage IIIB/IV NSCLC; no prior chemo-
therapy; ≥ 1 measurable lesion; ECOG ≤1; adequate organ function; no 
active CNS metastasis. Treatment: OGX-011 is given as a 2-hour infu-
sion. There is an initial loading phase with 3 doses of OGX-011 alone 
in 1 week, followed by weekly OGX-011 with standard chemotherapy: 
gemcitabine (1250 mg/m2) Days 1+8 and either cisplatin (75 mg/m2) or 
carboplatin (AUC=5) Day 1 q21 days, (maximum 6 cycles).
Results: 85 pts (phase 1=10 and phase 2=75) were enrolled between 
Dec, 2004 and Nov, 2006. As no unexpected dose limiting toxicities 
were noted in the ﬁrst 3 patients who received 480mg of OGX-011, the 
dose was escalated, as planned, to 640 mg for the remaining patients. 
Data are available on the ﬁrst 53 pts; all received ≥1 dose of OGX-011 
and were considered evaluable for safety and efﬁcacy. Demographics: 
female (47%); stage IV (87%); median age 61 (45-79) yrs; ECOG PS = 
1 (62%). The median number of cycles delivered was 4. Principal grade 
3/4 toxicities were hematologic: neutropenia (32%) + thrombocytope-
nia (17%). Other common toxicities included fatigue, nausea, vomiting, 
fever, chills, constipation, + anorexia. Two Serious Adverse Events 
previously reported as associated with gemcitabine/platinum therapy 
were documented: acute cortical blindness with stroke + thrombotic 
thrombocytopenic purpura. Responses: conﬁrmed PRs 13 (ORR = 
24%); median duration of PR: 105 days (46-336+); median PFS: 140 
days (2-422+); 79% of pts have progressed; 47% have died. Of the 
ﬁrst 34 patients who have all been followed for ≥ 1 yr, 18/34 (53%) 
survived > 1 yr; 14/18 (78%) remain alive as of March 06, 2006. Data 
will be presented for all 85 patients.
Conclusions: This combination is feasible and tolerable. The 1-yr 
survival rate ≥50% may justify a randomized phase III trial. OGX-011 
is being developed by OncoGenex Technology Inc. + Isis Pharmaceu-
ticals Inc.
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Background: Angiogenesis, the formation of new blood vessels, is 
an essential process during growth and progression of different solid 
